Company profile
PTC THERAPEUTICS, INC.
NASDAQ:PTCTBiotechnology: Pharmaceutical Preparations
Drug pipeline (8)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Deflazacort | approved | — | 8 | approved |
| Sepiapterin | approved | — | 5 | approved |
| EMVODODSTAT | phase2_3 | — | 5 | completed, terminated |
| Ataluren | phase2 | — | 3 | no active trials |
| EPI-589 | phase2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (62)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05166161 | phase3 | active_not_recruiting | 2022-02-14 | 2026-06-30 | PTC Therapeutics | A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria |
| NCT02251600 | phase1 | completed | 2014-12-01 | 2015-10-01 | PTC Therapeutics | A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy |
| NCT04117880 | phase2 | withdrawn | 2018-12-31 | 2021-01-31 | PTC Therapeutics | A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia |
| NCT05218655 | phase3 | completed | 2022-06-22 | 2025-04-15 | PTC Therapeutics | A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease |
| NCT02286609 | phase1 | completed | 2014-12-01 | 2015-02-01 | PTC Therapeutics | A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics |
FDA applications (4)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125722 | BLA | PTC Therapeutics | ||||
Loading… | ||||||
| NDA 208684 | NDA | PTC THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 208685 | NDA | PTC THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 219666 | NDA | PTC THERAPEUTICS INC | ||||
Loading… | ||||||